Mutation analysis of the CHK2gene in families with hereditary breast cancer

被引:0
|
作者
M Allinen
P Huusko
S Mäntyniemi
V Launonen
R Winqvist
机构
[1] University of Oulu/Oulu University Hospital,Department of Clinical Genetics
[2] University of Oulu,Department of Mathematical Sciences
[3] Biomedicum Helsinki,Department of Medical Genetics
[4] University of Helsinki,undefined
来源
British Journal of Cancer | 2001年 / 85卷
关键词
hereditary breast cancer; mutations; Li–Fraumeni-like syndrome;
D O I
暂无
中图分类号
学科分类号
摘要
Recently CHK2 was functionally linked to the p53 pathway, and mutations in these two genes seem to result in a similar Li–Fraumeni syndrome (LFS) or Li–Fraumeni-like syndrome (LFL) multi-cancer phenotype frequently including breast cancer. As CHK2 has been found to bind and regulate BRCA1, the product of one of the 2 known major susceptibility genes to hereditary breast cancer, it also more directly makes CHK2 a suitable candidate gene for hereditary predisposition to breast cancer. Here we have screened 79 Finnish hereditary breast cancer families for germline CHK2 alterations. Twenty-one of these families also fulfilled the criteria for LFL or LFS. All families had previously been found negative for germline BRCA1BRCA2 and TP53 mutations, together explaining about 23% of hereditary predisposition to breast cancer in our country. Only one missense-type mutation, Ile157→Thr157, was detected. The high Ile157→ Thr157mutation frequency (6.5%) observed in healthy controls and the lack of other mutations suggest that CHK2 does not contribute significantly to the hereditary breast cancer or LFL-associated breast cancer risk, at least not in the Finnish population. For Ile157→ Thr157our result deviates from what has been reported previously. © 2001 Cancer Research Campaign www.bjcancer.com
引用
收藏
页码:209 / 212
页数:3
相关论文
共 50 条
  • [41] Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer
    Gutierrez-Enriquez, Sara
    de la Hoya, Miguel
    Martinez-Bouzas, Cristina
    Sanchez de Abajo, Ana
    Ramon y Cajal, Teresa
    Llort, Gemma
    Blanco, Ignacio
    Beristain, Elena
    Diaz-Rubio, Eduardo
    Alonso, Carmen
    Tejada, Maria-Isabel
    Caldes, Trinidad
    Diez, Orland
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 103 (01) : 103 - 107
  • [42] Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas
    Harinck, Femme
    Kluijt, Irma
    van der Stoep, Nienke
    Oldenburg, Rogier A.
    Wagner, Anja
    Aalfs, Cora M.
    Sijmons, Rolf H.
    Poley, Jan-Werner
    Kuipers, Ernst J.
    Fockens, Paul
    van Os, Theo A. M.
    Bruno, Marco J.
    JOURNAL OF MEDICAL GENETICS, 2012, 49 (06) : 362 - 365
  • [43] Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, Canada
    Hartley, Taila
    Cavallone, Luca
    Sabbaghian, Nelly
    Silva-Smith, Rachel
    Hamel, Nancy
    Aleynikova, Olga
    Smith, Erika
    Hastings, Valerie
    Pinto, Pedro
    Tischkowitz, Marc
    Tomiak, Eva
    Foulkes, William D.
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2014, 12
  • [44] Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, Canada
    Taila Hartley
    Luca Cavallone
    Nelly Sabbaghian
    Rachel Silva-Smith
    Nancy Hamel
    Olga Aleynikova
    Erika Smith
    Valerie Hastings
    Pedro Pinto
    Marc Tischkowitz
    Eva Tomiak
    William D Foulkes
    Hereditary Cancer in Clinical Practice, 12
  • [45] Pedigree and BRCA gene analysis in breast cancer patients to identify hereditary breast and ovarian cancer syndrome to prevent morbidity and mortality of disease in Indian population
    Darooei, Mina
    Poornima, Subhadra
    Salma, Bibi Umae
    Iyer, Gayatri R.
    Pujar, Akhilesh N.
    Annapurna, Srirambhatla
    Shah, Ashwin
    Maddali, Srinivas
    Hasan, Qurratulain
    TUMOR BIOLOGY, 2017, 39 (02)
  • [46] Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry
    B. Graña
    L. Fachal
    E. Darder
    J. Balmaña
    T. Ramón y Cajal
    I. Blanco
    A. Torres
    C. Lázaro
    O. Diez
    C. Alonso
    M. Santamariña
    A. Velasco
    A. Teulé
    A. Lasa
    A. Blanco
    A. Izquierdo
    J. Borràs
    S. Gutiérrez-Enríquez
    A. Vega
    J. Brunet
    Breast Cancer Research and Treatment, 2011, 128 : 573 - 579
  • [47] Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry
    Grana, B.
    Fachal, L.
    Darder, E.
    Balmana, J.
    Ramon y Cajal, T.
    Blanco, I.
    Torres, A.
    Lazaro, C.
    Diez, O.
    Alonso, C.
    Santamarina, M.
    Velasco, A.
    Teule, A.
    Lasa, A.
    Blanco, A.
    Izquierdo, A.
    Borras, J.
    Gutierrez-Enriquez, S.
    Vega, A.
    Brunet, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 128 (02) : 573 - 579
  • [48] RASAL1andROS1Gene Variants in Hereditary Breast Cancer
    Isidori, Federica
    Bozzarelli, Isotta
    Ferrari, Simona
    Godino, Lea
    Innella, Giovanni
    Turchetti, Daniela
    Bonora, Elena
    CANCERS, 2020, 12 (09) : 1 - 19
  • [49] A multi-gene panel study in hereditary breast and ovarian cancer in Colombia
    Cock-Rada, A. M.
    Ossa, C. A.
    Garcia, H. I.
    Gomez, L. R.
    FAMILIAL CANCER, 2018, 17 (01) : 23 - 30
  • [50] BRCA1/2 associated hereditary breast cancer
    Li-song Teng
    Yi Zheng
    Hao-hao Wang
    Journal of Zhejiang University SCIENCE B, 2008, 9 : 85 - 89